Blog Header

In: Uncategorized

June 4, 2018

Syntimmune to Present at Jefferies 2018 Global Healthcare Conference

Read Story
May 17, 2018

Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus

Read Story
April 25, 2018

Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise

Read Story
February 26, 2018

Data on Lead Program SYNT001 to be Presented at Plenary Session of International Investigative Dermatology Conference

Read Story
January 3, 2018

Syntimmune Appoints Jean-Paul Kress, M.D., as President and Chief Executive Officer

Read Story
December 11, 2017

American Society of Hematology (ASH) Presentation December 11th, 2017

Read Story